For Korean stock market news & analysis, Click Here

[Feb 03, 2026] US Pre-market: Pfizer's Obesity Breakthrough & Major Analyst Upgrades

Feb 3, 2026: Pfizer's monthly obesity drug shows 12.3% weight loss. FedEx upgraded on Freight spin-off. PepsiCo and Merck report Q4 earnings.

 

■ Healthcare & Earnings Highlights

  • Pfizer (PFE)

    • Phase 2 Success: Pfizer announced that its experimental obesity drug 'PF-3944' demonstrated significant weight loss—up to 12.3% compared to the placebo group over 28 weeks.

    • Competitive Edge: Unlike weekly injections from Eli Lilly (LLY) and Novo Nordisk (NVO), PF-3944 is designed for once-a-month administration, offering a major convenience advantage.

    • Earnings Beat: Reported Q4 adjusted EPS of $0.66 (vs. $0.58 est) on revenue of $17.58B (vs. $16.91B est).

  • PepsiCo (PEP)

    • Solid Beat: Reported Q4 adjusted EPS of $2.26 (vs. $2.24 est) and revenue of $29.34B (vs. $28.97B est).

    • Organic Growth: Revenue rose 5.6% YoY, with organic revenue up 2.1%. Management reaffirmed its FY2026 guidance.

  • Merck (MRK)

    • Mixed Results: Q4 adjusted EPS ($2.04) met estimates, and revenue ($16.4B) slightly beat the $16.18B forecast.

    • Weak Guidance: 2026 EPS guidance of $5.00–$5.15 fell short of the $5.63 consensus due to one-time costs (~$3.65/share) from the Cidara Therapeutics acquisition.


■ AI, Cloud & Semiconductor Strategy

  • Microsoft (MSFT) & Nvidia (NVDA)

    • Top AI Picks: Wall Street ranks Microsoft as the #1 AI leader (PT $602.51) due to Azure performance and the OpenAI partnership. Nvidia follows at #2 with a $253.62 average PT, suggesting 45.7% upside.

  • Snowflake (SNOW)

    • OpenAI Partnership: Snowflake's deal allows 12,600 customers to access OpenAI models directly via Cortex AI.

    • Analyst Views: Raymond James noted Snowflake’s AI portfolio generates $100M in ARR. RBC Capital maintained a Buy ($300 PT), citing its core role in data warehousing.

  • Teradyne (TER)

    • Initiated at Buy: Aletheia Capital set a $400 target, projecting net income to triple by 2027.

    • Chiplet Demand: Testing demand is surging for advanced architectures like Nvidia’s Rubin Ultra, Apple’s A20 SoC, and Alphabet’s Axion CPU.


■ Industrials, Logistics & Consumer Services

  • FedEx (FDX)

    • Massive Upgrades: Bernstein raised its target to $427 (Outperform), and Wells Fargo hiked to $380 (Overweight).

    • Catalysts: Analysts view the potential spin-off of the Freight unit and a 200bp margin improvement in Express as game-changers. The path to $30 EPS by FY2029 is seen as increasingly visible.

  • Caterpillar (CAT)

    • Target Hike: Truist raised its PT to $786 (Buy) on high-quality Q4 earnings. DA Davidson raised its target to $650, citing strong data center construction demand, though warning of tariff-related margin pressure.

  • Woodward (WWD)

    • Surprise Beat: Reported Q1 EPS of $2.17 (vs. $1.65 est) and revenue of $996M (vs. $893M est), with a robust 20.9% EBITDA margin.

  • Palantir (PLTR)

    • Beat Consensus: Reported results that exceeded market expectations.


■ Fintech & Real Estate Outlook

  • SoFi Technologies (SOFI)

    • Upgrade to Overweight: JPMorgan set a $31 target, calling SoFi the future "American Express of Fintech" due to record member and deposit growth compared to stagnating peers.

  • PayPal (PYPL)

    • Earnings Miss: Q4 revenue ($8.68B) and adjusted EPS ($1.23) both missed estimates.

    • Leadership Change: Announced Enrique Lores as the new CEO, effective March 1.

  • Rocket Companies (RKT)

    • Mortgage Recovery: CEO expects the highest volume in 4 years as 30-day mortgage rates hit 5.99%, the lowest since early 2023.

  • MicroStrategy (MSTR)

    • BTC Impact: Shares fell as Bitcoin prices dropped to the mid-$70,000 range.



In Be Stock. Expert U.S. market news, trending stock analysis, and essential investor education. The best way to stay in the best stocks.

Post a Comment

New comments are not allowed.